Baidu
map

诺华Jakavi III期试验达主要终点

2014-03-10 tomato 生物谷

诺华3月7日宣布,有关Jakavi(ruxilitinib)的一项关键性III期RESPONSE研究,达到了维持红细胞压积(红细胞体积)受控而无需放血(phlebotomy,从身体中出去一些血液的一种程序,以减少红细胞浓度)的主要终点,同时降低了对羟基脲有抵抗或不耐受真性红细胞增多症患者脾脏大小,研究中ruxolitinib的安全性与以往研究一致。 该项研究的数据将提交至即将召开的医学会议,并提

诺华3月7日宣布,有关Jakavi(ruxilitinib)的一项关键性III期RESPONSE研究,达到了维持红细胞压积(红细胞体积)受控而无需放血(phlebotomy,从身体中出去一些血液的一种程序,以减少红细胞浓度)的主要终点,同时降低了对羟基脲有抵抗或不耐受真性红细胞增多症患者脾脏大小,研究中ruxolitinib的安全性与以往研究一致。

该项研究的数据将提交至即将召开的医学会议,并提交至全球各地的监管机构。

RESPONSE是一项全球性、随机、开放标签研究,在全球109个位点开展。试验中,222例对羟基脲有抗性或不耐受的真性红细胞增多症患者,随机接受ruxolitinib(10mg,每日2次)或最佳疗法(即研究人员选择的单药疗法或仅仅观察)。在整个研究中,剂量会随着需要进行调整。

该项研究的主要终点是,无需放血而血细胞比容得到控制的患者比例,以及32周时脾脏体积从基线缩小35%或更多(通过成像评估)。除安全性外,关键次要终点包括持久反应和完全的血液系统缓解。

红细胞增多症(polycythemia)是一种慢性、无法治愈的血液癌症,该病与血细胞生产过剩相关,导致血液增稠,血液凝块风险增加。这些血凝块可导致严重心血管并发症,如中风和心脏病发作,从而增加病发率和死亡率。红细胞增多症患者,常有脾脏肿大及额外衰弱的症状。许多患者经常规治疗后会变得不耐受或抵抗,这与病情恶化的风险升高有关。

关于Jakavi

Jakavi(ruxolitinib)是一种口服JAK1和JAK2酪氨酸激酶抑制剂,于2012年8月获欧盟批准,用于治疗中级或高危骨髓纤维化,包括原发性骨髓纤维化,真性红细胞增多症后骨髓纤维化和原发性血小板增多症后骨髓纤维化。目前,Jakavi已获全球50多个国家批准,包括欧盟、加拿大和一些亚洲、拉丁美洲和南美洲国家。

诺华从Incyte公司授权获得ruxolitinib在美国以外的开发和商业化权利。欧盟委员会和FDA均已授予ruxolitinib治疗骨髓纤维化的孤儿药地位。目前,Incyte已经在美国以商品名Jakafi销售,用于中级或高危骨髓纤维化的治疗。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1996918, encodeId=0fd71996918a8, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Dec 30 06:18:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737967, encodeId=94031e379675b, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10215, encryptionId=0abd10215e0, topicName=JAK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e8634348903, createdName=肉我只吃一口, createdTime=Thu Sep 04 19:18:00 CST 2014, time=2014-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947691, encodeId=7561194e6913f, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Dec 20 22:18:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915811, encodeId=4fcc1915811f9, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Aug 18 17:18:00 CST 2014, time=2014-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813823, encodeId=36211813823ea, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93911, encryptionId=5aba93911b8, topicName=达主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Dec 28 11:18:00 CST 2014, time=2014-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282619, encodeId=86dc128261982, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594360, encodeId=894d1594360a7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1996918, encodeId=0fd71996918a8, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Dec 30 06:18:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737967, encodeId=94031e379675b, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10215, encryptionId=0abd10215e0, topicName=JAK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e8634348903, createdName=肉我只吃一口, createdTime=Thu Sep 04 19:18:00 CST 2014, time=2014-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947691, encodeId=7561194e6913f, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Dec 20 22:18:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915811, encodeId=4fcc1915811f9, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Aug 18 17:18:00 CST 2014, time=2014-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813823, encodeId=36211813823ea, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93911, encryptionId=5aba93911b8, topicName=达主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Dec 28 11:18:00 CST 2014, time=2014-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282619, encodeId=86dc128261982, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594360, encodeId=894d1594360a7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1996918, encodeId=0fd71996918a8, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Dec 30 06:18:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737967, encodeId=94031e379675b, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10215, encryptionId=0abd10215e0, topicName=JAK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e8634348903, createdName=肉我只吃一口, createdTime=Thu Sep 04 19:18:00 CST 2014, time=2014-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947691, encodeId=7561194e6913f, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Dec 20 22:18:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915811, encodeId=4fcc1915811f9, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Aug 18 17:18:00 CST 2014, time=2014-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813823, encodeId=36211813823ea, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93911, encryptionId=5aba93911b8, topicName=达主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Dec 28 11:18:00 CST 2014, time=2014-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282619, encodeId=86dc128261982, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594360, encodeId=894d1594360a7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1996918, encodeId=0fd71996918a8, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Dec 30 06:18:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737967, encodeId=94031e379675b, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10215, encryptionId=0abd10215e0, topicName=JAK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e8634348903, createdName=肉我只吃一口, createdTime=Thu Sep 04 19:18:00 CST 2014, time=2014-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947691, encodeId=7561194e6913f, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Dec 20 22:18:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915811, encodeId=4fcc1915811f9, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Aug 18 17:18:00 CST 2014, time=2014-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813823, encodeId=36211813823ea, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93911, encryptionId=5aba93911b8, topicName=达主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Dec 28 11:18:00 CST 2014, time=2014-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282619, encodeId=86dc128261982, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594360, encodeId=894d1594360a7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-08-18 juliusluan78
  5. [GetPortalCommentsPageByObjectIdResponse(id=1996918, encodeId=0fd71996918a8, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Dec 30 06:18:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737967, encodeId=94031e379675b, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10215, encryptionId=0abd10215e0, topicName=JAK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e8634348903, createdName=肉我只吃一口, createdTime=Thu Sep 04 19:18:00 CST 2014, time=2014-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947691, encodeId=7561194e6913f, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Dec 20 22:18:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915811, encodeId=4fcc1915811f9, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Aug 18 17:18:00 CST 2014, time=2014-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813823, encodeId=36211813823ea, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93911, encryptionId=5aba93911b8, topicName=达主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Dec 28 11:18:00 CST 2014, time=2014-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282619, encodeId=86dc128261982, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594360, encodeId=894d1594360a7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1996918, encodeId=0fd71996918a8, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Dec 30 06:18:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737967, encodeId=94031e379675b, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10215, encryptionId=0abd10215e0, topicName=JAK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e8634348903, createdName=肉我只吃一口, createdTime=Thu Sep 04 19:18:00 CST 2014, time=2014-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947691, encodeId=7561194e6913f, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Dec 20 22:18:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915811, encodeId=4fcc1915811f9, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Aug 18 17:18:00 CST 2014, time=2014-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813823, encodeId=36211813823ea, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93911, encryptionId=5aba93911b8, topicName=达主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Dec 28 11:18:00 CST 2014, time=2014-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282619, encodeId=86dc128261982, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594360, encodeId=894d1594360a7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-03-12 docwu2019
  7. [GetPortalCommentsPageByObjectIdResponse(id=1996918, encodeId=0fd71996918a8, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Dec 30 06:18:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737967, encodeId=94031e379675b, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10215, encryptionId=0abd10215e0, topicName=JAK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e8634348903, createdName=肉我只吃一口, createdTime=Thu Sep 04 19:18:00 CST 2014, time=2014-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947691, encodeId=7561194e6913f, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Dec 20 22:18:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915811, encodeId=4fcc1915811f9, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Aug 18 17:18:00 CST 2014, time=2014-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813823, encodeId=36211813823ea, content=<a href='/topic/show?id=5aba93911b8' target=_blank style='color:#2F92EE;'>#达主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93911, encryptionId=5aba93911b8, topicName=达主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Dec 28 11:18:00 CST 2014, time=2014-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282619, encodeId=86dc128261982, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594360, encodeId=894d1594360a7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Mar 12 00:18:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]

相关资讯

百时美计划启动免疫组合疗法大型III期试验

百时美施贵宝(BMS)3月4日表示,计划今年年底启动一项大型III期临床试验,以测试该公司2种备受瞩目免疫疗法(nivolumab和Yervoy)的组合疗法,是否能有效治疗肺癌。免疫疗法,能够增强免疫系统的抗癌能力。 该公司负责人在今年1月份称,还没有计划开展后期试验测试实验性抗癌单抗药nivolumab和另一种已获批的黑色素瘤治疗药物Yervoy的组合疗法,这吓坏了投资者。而本周二,BMS全球

罗氏单抗lebrikizumab IIb期显著降低哮喘发作

根据3月4日公布的一项IIb临床实验数据,罗氏(Roche)开发的实验性单抗药物lebrikizumab,使严重不受控哮喘患者的哮喘发作降低了60%,并帮助改善了特定患者群体的肺功能,预示着lebrikizumab有望成为特定哮喘群体的首个个性化治疗药物。 lebrikizumab由罗氏旗下基因泰克(Genentech)研制。该项IIb期试验,在463例经高剂量吸入性糖皮质激素及二线哮喘控制疗法

拜耳在日本提交Eylea DME新适应症申请

拜耳(Bayer)3月3日宣布,已向日本卫生劳动福利部(MHLW)提交了眼科药物Eylea(aflibercept,阿柏西普注射液)上市许可申请(MAA),寻求批准用于糖尿病性黄斑水肿(DME)患者的治疗。Eylea MAA的提交,是基于III期VISTA-DME和VIVID-DME研究的数据。去年11月,拜耳也向MHLW提交了Eylea新适应症申请,寻求批准用于病理性近视继发脉络膜新生血管(my

默沙东屋尘螨抗过敏药MK-8237显著改善患者症状

根据3月4日美国过敏、哮喘和免疫学会(AAAAI)2014年会,一项II期临床数据显示,默沙东(Merck & Co)开发用于治疗屋尘螨(house dust mites)过敏的免疫疗法MK-8237,显著减少了患者的鼻部症状,如打喷嚏和鼻塞。 该项研究表明,经24周治疗后,与安慰剂相比,高剂量和低剂量MK-8237分别使鼻部症状减少了49%和27%,数据具有统计学显著差异。 MK-8

Forest向FDA提交美金刚ER/多奈哌齐FDC 新药申请

森林实验室(Forest Lab)和合作伙伴Adamas制药公司3月4日宣布,已向FDA提交了缓释美金刚(memantine ER)+多奈哌齐(donepezil)固定剂量组合产品(FDC)的新药申请(NDA),该药开发用于中度至重度阿尔茨海默型老年痴呆症(Alzheimer's type dementia)的治疗。 美金刚(memantine)和多奈哌齐(donepezil)联合用药,是用于阿

勃林格-礼来糖尿病新药empagliflozin遭FDA拒绝

勃林格殷格翰-礼来糖尿病联盟降糖新药empagliflozin遭FDA拒绝。该联盟3月5日称,FDA已就empagliflozin的新药申请(NDA)发布了一封完整回应函(CRL)。在函中,FDA提及了此前在勃林格殷格翰生产empagliflozin的工厂里发现的缺陷。FDA指出,这些问题需要在empagliflozin NDA获批之前解决。不过FDA并没有要求开展任何新的临床试验来支持empag

Baidu
map
Baidu
map
Baidu
map